Abstracts tagged "IL-1/IL-18"

Abstract Number: 885 • 2014 ACR/ARHP Annual Meeting
A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess Safety and Effect Duration
Eric L. Matteson¹, Bhaskar Dasgupta², Wolfgang A. Schmidt³, Carlo Salvarani⁴, Nagui Gendi⁵, Mauro Galeazzi⁶, Sylvie Stitah⁷, Yue Li⁸, Marie-Anne Valentin⁹, Bolan Linghu¹⁰ and Stephen J. Oliver⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Southend University Hospital, Essex, United Kingdom, ³Rheumatology, Immanuel Krankenhaus, Berlin, Germany, ⁴Rheumatology Unit, Arcispedale-Santa-Maria-Nuova, Reggio Emilia, Italy, ⁵Rheumatology, Basildon & Thurroch University Hospitals NHS Trust, Basildon, Essex, United Kingdom, ⁶Sezione di Reumatologia, Università di Siena, Siena, Italy, ⁷Translational Medicine, Novartis Pharma AG, Basel, Switzerland, ⁸IIS, Novartis Pharma AG, Basel, Switzerland, ⁹Biomarker Development, Novartis Pharma AG, Basel, Switzerland, ¹⁰Translational Medicine, Novartis Pharma AG, Cambridge, MA
Background/Purpose To assess the effects of a single dose of secukinumab or canakinumab in patients with new onset, untreated polymyalgia rheumatica (PMR). Methods In this…
Abstract Number: 834 • 2014 ACR/ARHP Annual Meeting
Interleukin-18 (IL-18) As a Biomarker for Diagnosis and Evaluation of Disease Activity in Patients with Adult Onset Still’s Disease and Systemic Onset Juvenile Idiopathic Arthritis
Holger Kudela¹, Susanne Drynda², Anke Lux³, Gerd Horneff⁴ and Joern Kekow², ¹Univ of Magdeburg, Clinic for Rheumatology, Vogelsang-Gommern, Germany, ²Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ³Univ of Magdeburg, Institute for Biometry and Medical Informatics, Magdeburg, Germany, ⁴Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Establishing the diagnosis of adult onset Still’s disease (AOSD) as well as of systemic onset juvenile idiopathic arthritis (sJIA) is very challenging. Mostly it…
Abstract Number: 275 • 2013 ACR/ARHP Annual Meeting
Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab
Tomohiro Kubota¹, Syuji Takei², Yuichi Yamasaki¹, Junko Yasumura³, Naomi Kuwada⁴, Yukiko Nonaka⁵, Tomoko Takezaki⁵, Tsuyoshi Yamatou⁵, Tomokazu Nagakura⁶, Yasuhito Nerome⁵, Hiroyuki Imanaka⁵ and Harumi Akaike⁵, ¹Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, ⁴Dept of Pediatrics, Faculuty of Medicine, Kumamoto University, Kumamoto City, Japan, ⁵Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ⁶Department of Pediatrics, House of Meguminoseibo, Usuki, Japan
Background/Purpose: Tocilizumab (TCZ), anti-human interleukin-6 receptor monoclonal antibody, was the first biologic agent used in the treatment of systemic juvenile idiopathic arthritis (sJIA) in Japan.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].